Ask AI
ProCE Banner Activity

Immune Thrombocytopenia Treatment: Individualizing Care Beyond Platelet Counts

Clinical Thought

The approach to immune thrombocytopenia treatment is evolving as updated guidance and emerging evidence support more individualized care. This faculty-led activity explores strategies to reduce corticosteroid exposure, navigate subsequent treatment options, address fatigue and quality of life alongside platelet response, and assess the potential for treatment tapering and treatment-free response.

Released: September 14, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Target Audience

This activity has been designed to meet the educational needs of hematologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals who manage patients with immune thrombocytopenia (ITP).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate fatigue assessment tools into routine ITP evaluations and apply evidence-based fatigue management strategies

  • Implement corticosteroid-sparing approaches by utilizing alternative first-line and second-line therapies in appropriate patients

  • Identify candidates for treatment-free remission and develop monitoring plans for patients who may safely discontinue therapy

  • Apply holistic QoL assessments in clinical practice, incorporating patient-reported outcomes into ITP management decisions

  • Optimize using TPO-RAs and newer therapies by selecting appropriate patients and sequencing treatments effectively

Financial Disclosures

Primary Author

Hanny Al-Samkari, MD: consultant/advisor/speaker: Agios, Alnylam, Alpine, Amgen, Atavistik, Diagonal, Novartis, Pharmacosmos, Sanofi, Sobi, Takeda, Tectonic, Terremoto, Vaderis; researcher: Agios, Alnylam, Amgen, Atavistik, Novartis, Sobi, Vaderis.

Adam Cuker, MD, MS: consultant/advisor/speaker: Incyte, Pfizer.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.